Ammonaps 500 mg tablets

*
Pharmacy Only: Prescription
  • Company:

    Immedica Pharma AB
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 16 December 2022

File name

Ammonaps 500mg tabl_SPC_01Oct2022.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 16 December 2022

File name

Ammonaps 500mg tabl_PIL_01Oct2022.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 22 October 2020

File name

Ammonaps 500 tabs_PIL-med.ie_14Oct2020.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

2.         What you need to know before you take AMMONAPS

AMMONAPS contains sodium

Each AMMONAPS tablet contains 62 mg of sodium.

Talk to your doctor or pharmacist if you need 6 or more tablets daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet.

6.         Contents of the pack and other information

This leaflet was last revised in 10/2020

Updated on 22 October 2020

File name

Ammonaps 500 tabs_PIL-med.ie_14Oct2020.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

2.         What you need to know before you take AMMONAPS

AMMONAPS contains sodium

Each AMMONAPS tablet contains 62 mg of sodium.

Talk to your doctor or pharmacist if you need 6 or more tablets daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet.

6.         Contents of the pack and other information

This leaflet was last revised in 10/2020

 

 

Updated on 22 October 2020

File name

Ammonaps 500 tabs_SPC-med.ie_14Oct2020.pdf

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

New text highlighted in blue

Deleted text highlighted in red

Note: sections only provided where amendments have been made

2.            QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains 500 mg sodium phenylbutyrate.

Excipient(s) with known effect

Each AMMONAPS tablet contains 2.7 mmol (62 mg) of sodium.

For the full list of excipients, see section 6.1.

4.4         Special warnings and precautions for use

AMMONAPS tablets should not be used in patients with dysphagia due to the potential risk of oesophageal ulceration if tablets are not promptly delivered to the stomach.

This medicinal product contains 62 mg sodium per tablet, equivalent to 3% of the WHO recommended maximum daily intake for sodium.

The maximum recommended daily dose of this product contains 2.5 g sodium which is equivalent to 124% of the WHO recommended maximum daily intake for sodium.

AMMONAPS is considered high in sodium. This should be particularly taken into account for those on a low salt diet.

Each AMMONAPS tablet contains 62 mg (2.7 mmol) of sodium, corresponding to 2.5 g (108 mmol) of sodium per 20 g of sodium phenylbutyrate, which is the maximum daily dose. AMMONAPS should therefore be used with caution in patients with congestive heart failure or severe renal insufficiency, and in clinical conditions where there is sodium retention with oedema.

Since the metabolism and excretion of sodium phenylbutyrate involves the liver and kidneys, AMMONAPS should be used with caution in patients with hepatic or renal insufficiency.

Serum potassium should be monitored during therapy since renal excretion of phenylacetylglutamine may induce a urinary loss of potassium.

Even on therapy, acute hyperammonaemic encephalopathy may occur in a number of patients.

AMMONAPS is not recommended for the management of acute hyperammonaemia, which is a medical emergency.

In children unable to swallow tablets, it is recommended to use AMMONAPS granules instead.

10.       DATE OF REVISION OF THE TEXT

06/06/201914/10/2020

Updated on 08 January 2020

File name

Ammonaps 500 tabs-SPC-med.ie.pdf

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 08 January 2020

File name

Ammonaps 500 tabs-PIL-med.ie.pdf

Reasons for updating

  • New PIL for new product